No Picture
Lexaria Bioscience Corp.

Lexaria Bioscience Corp. Receives New U.S. Patent Allowance for Cannabinoid Delivery and Updates its Expanding Patent Portfolio

KELOWNA, BC / ACCESSWIRE / April 11, 2018 / Lexaria Bioscience Corp. (OTCQX: LXRP) (CSE: LXX) (the “Company” or “Lexaria”), a drug delivery platform innovator, announces it has received another new Notice of Allowance from the […]

No Picture
Lexaria Bioscience Corp.

NetworkNewsWire Announces Publication on Custom Innovations in Nicotine Delivery

NEW YORK, March 07, 2018 (GLOBE NEWSWIRE) — via NetworkWire – NetworkNewsWire (“NNW”), a multifaceted financial news and publishing company, today announces the publication of an editorial featuring Lexaria Bioscience Corp. (CSE:LXX) (OTCQX:LXRP), a client of NNW […]

No Picture
Lexaria Bioscience Corp.

Lexaria Enters Licensing Agreement with Cannabis Edibles Infusion Company

KELOWNA, BC / ACCESSWIRE / February 27, 2018 / Lexaria Bioscience Corp. (OTCQX: LXRP) (CSE: LXX) (the “Company” or “Lexaria”) a drug delivery platform innovator, announces it has entered a definitive technology licensing agreement (the “Agreement”) […]

No Picture
Lexaria Bioscience Corp.

NeutriSci and Lexaria Bioscience Enter Global Licensing Agreement

Vancouver, British Columbia–(Newsfile Corp. – February 26, 2018) – NeutriSci International Inc. (TSXV: NU) (OTCQB: NRXCF) (FSE: 1N9) (the “Company” or “NeutriSci”) and Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) (“Lexaria”) are pleased to announce that they have […]